We previously reported that combination chemotherapy of gemcitabine and nafamostat mesilate, a NF-κB inhibitor, had favorable outcomes for unresectable pancreatic cancer in phase 1 and 2 study [22, 23]. Here, NFKB1 is linked to pancreatic neoplasm.